Evidence mapPaperPMID 42430964Full record

ArticleThe journal of prevention of Alzheimer's disease2026

Suboptimal adherence to brain health recommendations in patients pursuing anti-amyloid antibody therapy for Alzheimer's disease: Report from the Brain Health Vital Signs project.

Kirk R Daffner, Kayla Riera, George R Ghorayeb, Brittany M McFeeley, Emma Weizenbaum, Kim Willment, Seth A Gale

Abstract read
In one paragraph

Article in The journal of prevention of Alzheimer's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kirk R DaffnerCenter for Brain/Mind Medicine, Laboratory of Healthy Cognitive Aging, Department of Neurology, Brigham and Women's Hospital/Harvard Medical School, 60 Fenwood Road, Boston, MA, 02115, USA. Electronic address: kdaffner@bwh.harvard.edu.
Kayla RieraCenter for Brain/Mind Medicine, Laboratory of Healthy Cognitive Aging, Department of Neurology, Brigham and Women's Hospital/Harvard Medical School, 60 Fenwood Road, Boston, MA, 02115, USA. Electronic address: kriera@bwh.harvard.edu.
George R GhorayebCenter for Brain/Mind Medicine, Laboratory of Healthy Cognitive Aging, Department of Neurology, Brigham and Women's Hospital/Harvard Medical School, 60 Fenwood Road, Boston, MA, 02115, USA. Electronic address: gghorayeb@bwh.harvard.edu.
Brittany M McFeeleyCenter for Brain/Mind Medicine, Laboratory of Healthy Cognitive Aging, Department of Neurology, Brigham and Women's Hospital/Harvard Medical School, 60 Fenwood Road, Boston, MA, 02115, USA. Electronic address: bmcfeeley@bwh.harvard.edu.
Emma WeizenbaumCenter for Brain/Mind Medicine, Laboratory of Healthy Cognitive Aging, Department of Neurology, Brigham and Women's Hospital/Harvard Medical School, 60 Fenwood Road, Boston, MA, 02115, USA. Electronic address: eweizenbaum@bwh.harvard.edu.
Kim WillmentCenter for Brain/Mind Medicine, Laboratory of Healthy Cognitive Aging, Department of Neurology, Brigham and Women's Hospital/Harvard Medical School, 60 Fenwood Road, Boston, MA, 02115, USA. Electronic address: kwillment@bwh.harvard.edu.
Seth A GaleCenter for Brain/Mind Medicine, Laboratory of Healthy Cognitive Aging, Department of Neurology, Brigham and Women's Hospital/Harvard Medical School, 60 Fenwood Road, Boston, MA, 02115, USA. Electronic address: sagale@bwh.harvard.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundConsensus is consolidating around a set of lifestyle and medical factors that can promote brain health and reduce the risk of dementia for older adults and further decline for those with early Alzheimer's disease (AD) and related disorders. Little is known about the degree to which recommended brain-healthy behaviors have been adopted by patients with early AD pursuing anti-amyloid antibody therapy (AAT), a proactive group interested in doing what is under their control to help preserve cognitive and functional status. Here, initial results of a clinically relevant quality improvement study are reported.

objectiveTo determine the extent to which patients pursuing AAT for AD adhere to consensus-based brain health recommendations.

participantsOne hundred fifty patients with mild cognitive impairment (MCI) or mild dementia due to AD seeking AAT were studied and compared to a group of 117 patients with MCI or mild dementia who were not pursuing AAT. MEASUREMENTS: Using a clinical survey tool developed for the project, patients were assessed on 15 modifiable risk factors for cognitive decline and dementia, including 11 via e-survey (diet, physical activity, cognitive activity, sleep, social engagement, smoking status, alcohol consumption, hearing, vision, mood/stress, and purpose in life) and 4 via electronic medical record (EMR) (blood pressure, BMI, LDL cholesterol level, and HbA1c). For each factor, the percentage of each of the two patient groups that was not optimally adhering to brain health-related guidelines was calculated. For each individual, the total number of factors not optimally being followed was determined.

resultsLess than 3% of patients with early AD pursuing AAT were following or had anthropometric measures/lab values in line with all 15 brain health recommendations. The five factors with the lowest adherence rates involved physical activity, mood/stress, HbA1c, blood pressure, and BMI, with 44-63% of the AAT group suboptimally following consensus-based guidelines. For 11 of 15 factors, >25% of the group were not adhering to guidelines. No robust differences in degree or pattern of adherence to guidelines were observed between patients pursuing and not pursuing AAT. There were no data in the EMR for HbA1c in >42% of patients and for LDL in >23% of patients in either group.

conclusionsSuboptimal adherence to brain health recommendations may be common among patients with early AD, whether they are pursuing AAT or not. These results suggest that healthcare systems may need to develop more effective strategies and individualized interventions for addressing modifiable risk factors for cognitive decline and dementia, and more efficacious procedures for ensuring that relevant, actionable data associated with brain health are updated in the EMR.

Indexed as

Anti-amyloid antibody therapyBrain healthConsensus-based guidelines, Alzheimer’s disease and related disordersModifiable risk factors

Identifiers

PMID42430964
PMCPMC13380726

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.